Halozyme Therapeutics, Inc. annual operating income for fiscal 2025 was $803 million, an increase of 45.5% from $552 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Operating Income (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Income (EBIT) | $803M | $552M | $338M | $268M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Operating Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Operating Income (EBIT) | $184M | $241M | $218M | $202M | $142M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More HALO metrics: Revenue · Gross Profit · Net Income · EPS · Free Cash Flow
All HALO financial statements → Interactive HALO charts →
About TickerBase · Data methodology & sources